The costs and benefits were synthesised to estimate incremental cost-effectiveness ratios in terms of the cost per QALY gained by moving from the cost-minimising strategy to the QALY-maximising strategy. The incremental cost-effectiveness ratio was:
$11,937 for patients in the Well pre-test category of "high; DVT suspected";
$6,334 for patients in the Wells pre-test category of "high; no DVT suspected";
$53,250 for patients in the Wells pre-test category of "moderate; DVT suspected";
$6,232 for patients in the Wells pre-test category of "moderate; no DVT suspected"; and
$9,088 for patients in the Wells pre-test category of "low".
A discount rate of 3% per annum was applied to the costs and QALYs.